

Freedom of Information Request	FOI 22-329	4 th August 2022
--------------------------------	------------	-----------------------------

I am researching the incidence and treatment of Diffuse Large B Cell Lymphoma (DLBCL). Could you please answer the following questions.

Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?

Yes

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?

The Health Board has treated 21 new diagnosis of DLBCL in the last 6 months

<5 Active Monitoring

14 Chemotherapy

<5 Surgery

<5 Other treatments

Please note the Health Board has applied Section 40 of the Freedom of Information Act 2000. The Health Board will not provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **Other immuno-chemotherapy**
- **Other chemotherapy**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment**

- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only**
- **Tisagenlecleucel**
- **Axicabtegene ciloleucel**
- **Lisocabtagene maraleucel**

Please find the quantities dispensed from the Health Board hospital pharmacies for the period February 2022 – July 2022 for Haematology only.

Please note that the Health Board are only able to provide information by quantity and not by patient.

Type	Quantity
BENDAMUSTINE HYDROCHLORIDE 100 mg Intravenous Infusion 5 Vial Pack	6
BENDAMUSTINE HYDROCHLORIDE 25 mg Intravenous Infusion 5 Vial Pack	14
CYCLOPHOSPHAMIDE (1251mg-1500mg) in SODIUM CHLOR 0.9%(500mL) Intravenous Infusion 1 Bag Pack	5
CYCLOPHOSPHAMIDE (2501mg - 2750mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	13
CYCLOPHOSPHAMIDE (2751mg - 3000mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	11
CYCLOPHOSPHAMIDE (501mg-750mg) in SODIUM CHLOR 0.9%(500mL) Intravenous Infusion 1 Bag Pack	4
CYCLOPHOSPHAMIDE 150 mg in 7.5mL Intravenous Injection 1 Syringe Pack	36
CYCLOPHOSPHAMIDE 400 mg in 20mL Intravenous Injection 1 Syringe Pack	76
CYCLOPHOSPHAMIDE 50 mg Tablets 100 Tablet Pack	26
CYCLOPHOSPHAMIDE 500 mg in 25mL Intravenous Injection 1 Syringe Pack	113
CYCLOPHOSPHAMIDE 700 mg in 35mL Intravenous Injection 1 Syringe Pack	142
CYCLOPHOSPHAMIDE 800 mg in 40mL Intravenous Injection 1 Pre-Filled Syringe Pack	158
DOXORUBICIN 25 mg in 12.5mL Intravenous Injection 1 Syringe Pack	14
DOXORUBICIN 30 mg in 15mL Intravenous Injection 1 Syringe Pack	65
DOXORUBICIN 50 mg in 25mL Intravenous Injection 1 Syringe Pack	103
POLATUZUMAB VEDOTIN 140 mg Intravenous Infusion 1 Vial Pack	9
POLATUZUMAB VEDOTIN 30 mg Intravenous Infusion 1 Vial Pack	19
RITUXIMAB (MABTHERA) 1400 mg in 11.7mL Subcutaneous Injection 1 Vial Pack	114
RITUXIMAB (RIXATHON) 100 mg in 10mL Intravenous Infusion 2 Vial Pack	130
RITUXIMAB (RIXATHON) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	135
VINCRISTINE 1mg in SODIUM CHLORIDE 0.9% (50mL) Intravenous Infusion 1 Bag Pack	113
VINCRISTINE 2mg in SODIUM CHLORIDE 0.9% (50mL) Intravenous Infusion 1 Bag Pack	85
VINCRISTINE SULFATE 2 mg in 2mL Intravenous Injection 1 Vial Pack	7

Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)**

The Health Board does not capture this information. However, you may wish to contact [Cardiff and Vale University Health Board](#) as the Health Board refer patient into their services and may hold some information.

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

The Health Board does not currently hold any trials for Diffuse Large B-Cell Lymphoma (DLBCL).